We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Western blot analysis was used to detect the changes in PDX-1 expression.
2
The PDX model was used successfully to test targeted drugs in vivo.
3
This a-to-β conversion was not caused by activating Pdx1 in the later glucagon-expressing state.
4
In addition, RNAi technology was used to specifically knock down the endogenous PDX-1 expression.
5
A specific serum assay for PDX is not commercially available.
1
This favorable survival result was seen in most prespecified subgroups for pralatrexate.
2
These results indicate that pralatrexate is generally well tolerated and effective in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
3
A trend toward improvement in OS favoring pralatrexate was observed with an HR of 0.84 (95% confidence interval: 0.61-1.14) in the intent-to-treat population.
4
Pralatrexate is a novel antifolate approved in the USA for the treatment of relapsed or refractory peripheral T-cell lymphoma.
5
Pralatrexate, which has already received FDA's orphan drug status to treat T-cell lymphoma, is being tested as a treatment for large B-cell lymphoma.